The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study

European Journal of Medical Research

Francesco E Pontieri¹  Morena Giovannelli²  Pamela Latino²  Alessandra Fanciulli²  Dario Benincasa¹  Clelia Pellicano² 

[1] Scientific Institute for Research, Hospitalization and Health Care (IRCSS), Fondazione Santa Lucia, Via Ardeatina, 306-00179, Rome, Italy;Movement Disorder Unit, Sant’Andrea Hospital, Via di Grottarossa, 1035-00189, Rome, Italy

关键词: Rotigotine;    Ropinirole;    Pramipexole;    Parkinson’s disease;    Levodopa;    Extended release;    Dopamine agonists;   

Others  :  817692
DOI  :  10.1186/2047-783X-18-60

 received in 2013-07-21, accepted in 2013-12-06,  发布年份 2013

【 摘 要 】

Background

Dopamine agonists (DA) are the first-choice drug for treatment of the early stage of Parkinson’s disease (PD) in subjects younger than 70 years. Recently, a number of third generation DA have been marketed, including transdermal patch of rotigotine and extended release oral formulation of ropinirole and pramipexole.

We investigated the impact of third generation DA on management of the early stage of PD in an outpatient service for Movement Disorders in Italy.

Methods

Two 12-month observation periods were selected (January - December, 2007, and January - December, 2011) as representative for prescription of immediate and extended release formulations of DA respectively. Within each period, PD patients were divided into subgroups according to age (<65 years; 65–75 years; >75 years) or functional requirement (high; moderate; low). For each period, the number of subjects receiving monotherapy with DA, monotherapy with levodopa (LD), or combined DA/LD therapy and the relative doses were calculated. The severity of parkinsonian motor symptoms was calculated by means of the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) score. The frequency and severity of side-effects leading to discontinuation or reduction of DA drugs at each time point were also calculated.

Results

We found a significant reduction of daily LD dose (both as mono- and combined therapy) between the second and the first observation period. There was also a significant increase of monotherapy with DA and corresponding reduction of monotherapy with LD in patients aged 65–75 years, as well as in PD patients with moderate functional requirements. A significant reduction of frequency of side-effects was measured with extended release DA as compared to immediate release formulations. There were no significant differences of the UPDRS-III scores between the 2 observation periods in any subgroup.

Conclusions

Our results suggest that extended release DA might optimize therapeutic management of the early stages of PD even in patients older than 70 years of age.

【 授权许可】

   
2013 Pellicano et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C, European Federation of Neurological Societies; Movement Disorder Society–European Section: Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part 1: early (uncomplicated) Parkinson’s disease. Eur J Neurol 2006, 13:1170-1185.
• [2]Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002, 41:261-309.
• [3]Bonuccelli U, Del Dotto P, Rascol O: Role of dopamine receptor agonists in the treatment of early Parkinson’s disease. Parkinsonism Relat Disord 2009, 15(Suppl 4):S44-S53.
• [4]Bonuccelli U, Ceravolo R: The safety of dopamine agonists in the treatment of Parkinson’s disease. Expert Opin Drug Saf 2008, 7:111-127.
• [5]Stocchi F: Continuous dopaminergic stimulation and novel formulations of dopamine agonists. J Neurol 2011, 258(Suppl 2):S316-S322.
• [6]Giladi N, Boroojerdi B, Korczy AD, Burn DJ, Clarke CE, Schapira AHV, SP513 Investigators: Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404.
• [7]Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group: Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 2011, 77:759-766.
• [8]Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators: Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008, 24:2883-2895.
• [9]Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B: Treatment of patients with early and advanced Parkinson’s disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism Relat Disord 2013, 19:37-42.
• [10]Grosset D, European PD Therapy Compliance Study Group: Therapy adherence issues in Parkinson’s disease. J Neurol Sci 2010, 289:115-118.
• [11]Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999, 56:33-39.
• [12]Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, LeWitt P, Oertel W, Quinn N, Sethi K, Stocchi F: Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005, 20:726-733.
• [13]Goetz CG, Blasucci L, Stebbins GT: Switching dopamine agonists in advanced Parkinson’s disease: Is rapid titration preferable to slow? Neurology 1999, 52:1227-1229.
• [14]Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W, Pramipexole ER Study Group: Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol 2012, 35:174-181.
• [15]Fayard C, Bonaventure A, Benatru I, Roze E, Dumurgier J, Moisan F, Soumaré A, Houssinot J, Dupupet JL, Mazurie JL, Balaboi I, Houeto JL, Krim E, Ranoux D, Goldberg M, Imbernon E, Moreau T, Giroud M, Tzourio C, Elbaz A: Impact of recommendations on the initial therapy of Parkinson’s disease: a population-based study in France. Parkinsonism Relat Disord 2011, 17:543-546.